Library Progress International
Vol.44 No.3, September 2024: P. 21849-21870

Print version ISSN 0970 1052
Online version ISSN 2320 317X

Original Article

Available online at www.bpasjournals.com

Integrating Genomic Data with AI Algorithms to Optimize Personalized Drug Therapy: A Pilot Study

Rakesh Paul[1*], Anwar Hossain[2], Md Tajul Islam[3], Md Mehedi Hassan Melon[4], Muhamad Hussen[5].

[*1]Master of Science in Information Technology, Washington University of Science and Technology, USA, rpaul.student@wust.edu
[2]MBA in Management Information System, International American University, USA anwar.eee07@gmail.com
[3]Master of Science in Information Technology, Washington University of Science and Technology, USA, ti.metho2012@gmail.com
[4]Master of Business Administration, International American University, Los Angeles, USA mehedihassanntu@gmail.com
[5](a)Department of computers Techniques engineering, College of technical engineering, The Islamic University, Najaf, Iraq, (b) Department of Computers Techniques Engineering, College of Technical Engineering, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq, mhussien074@iunajaf.edu.iq

How to cite this article: Rakesh Paul, Anwar Hossain, Md Tajul Islam, Md Mehedi Hassan Melon, Muhamad Hussen (2024). Integrating Genomic Data with AI Algorithms to Optimize Personalized Drug Therapy: A Pilot Study. *Library Progress International*, 44 (3), 21849-21870.

Abstract

Personalized medicine has become more prominent in the course of the last few years to improve treatment methods by taking into account patients' genetic makeup. Combining the genomic information into powerful new AI platforms in drug therapies opens up the way of reducing drug toxicity while enhancing the prospects for drug efficacy. This pilot study aims to determine the possibilities of using AI to analyze genomics data to help improve the approachability and effectiveness of drug therapies, which has been a major challenge given the lacunae in precision in the treatment strategies used. This pilot study is intended to enroll 50 patients with diverse chronic diseases. Targeted gene-specific sequencing was performed to obtain polymorphic loci on drug metabolism and treatment efficacy. AI tools such as machine learning models are used to help find patterns and relationships between genomic data and treatment results and risks. These were then compared to clinical outcomes in order to determine the viability of the AI-integrated method for recommending drug regimens. This study shows that the incorporation of genomic data in conjunction with AI greatly improves the accuracy of individualized pharmacotherapy. The AI-generated suggestions matched well with the enhanced patient experience to show the potential of this concept in the real world. It employs a broader clinically ascertained population and is warranted to replicate these findings, supporting the benefits of using genomic-informed AI applications for drug therapy to drive further development of personalized medicine.

Keywords: personalized medicine, genomic data, artificial intelligence, drug therapy, machine learning, precision medicine, AI algorithms

Introduction and Background

Personalized medication has emerged as one of the promising medical niches within several years, and the emphasis has been made on the use of genomic information within medical practice to enhance the effectiveness of treatment. Personalized medicine thus involves developing differential treatment methods that tackle illness according to a patient's or a population's genetic make-up as well as their environment and lifestyles, instead of one-size-fits-all treatment plans proposed previously by non-personalized medicine. Taherdoost,(2024). It has proven most fruitful in pharmacogenomics, in which identification of the patient's genetic differences allows for suggested indications

of possible side effects or effectiveness of a certain medicine. Tsigelny, I. F. (2019). The advancement of artificial intelligence in master health has simply boosted this process. Advanced artificial intelligence algorithms, including machine learning, are ideal models for handling large data sets, such as genomic data, more efficiently than traditional statistical measures. Quazi, S. (2022). AI processes massive amounts of genomic data that many may find challenging to decipher; they can accurately pinpoint patterns and correlations that aid treatment decision-making among the research and clinical workforce. Rehan, H. (2024). It has the possibilities to manage the major setbacks of individualized treatment, especially in pharmacotherapy, which keeps high variability in its response. Abdallah, S. (2023). In the most recent research, genomics analysis with the help of AI can predict pharmacological action far better as compared to conventional approaches leading to the proper genomics-based pharmacotherapy. Živanović, M. N., & Filipović, N. (2024). AI in pharmacogenomics and drug development, particularly in complex clinical practice environments, where both inter-individual variability and drug treaty complexities are most expressed Shams, A. (2024). This pilot study will try to add to this burgeoning field for the purpose of investigating the prognostic capabilities that intelligence genomics may hold regarding treatment reactions so as to work towards improving the safety and efficacy of drug administration with personalized methods.

With the daily progression in genomics and AI, unique pharmacotherapy for those diseases is already on the horizon. Personalized medicine seeks to design an intervention plan for patients's tailor-made according to their unique genetic makeup, environment, and lifestyles, hence trying to shift from the traditional treatment model, which provides a solution that fits everybody. Schork, N. J. (2019). This is particularly relevant in pharmacotherapy because genetic differences can profoundly affect the process by which patients metabolize drugs and respond to them, with regards to both effectiveness and toxicity. Serrano, D. R., B., Kara, A. (2024). Pharmacogenomics requires the analysis of genomic data in order to identify and manage patient-specific genetic variation, or polymorphism, which may affect drug metabolism and thus both the effectiveness and safety profile of a particular agent. Tong, L., Shi, W. (2023). Genomics is the approach that shows how individuals' genes can influence their reactions to drugs, and new research shows that certain genetic alleles will determine the reaction to particular medication. Qian, X., Liao, J., & Fang, Y. (2024). Nevertheless, large amounts of data and its complexity often pose difficulties for analysis, especially when using more conventional statistical approaches. This is where AI, and in particular, machine learning, has the potential to make the difference. The participation of experts means that, through deep learning, AI helps to analyze large volumes of genomic data more quickly, comprehensively, and accurately than before Khansari, N. (2024). AI has potential usage in interpreting multiple relationships in the data and establishing accurate diagnosis for patients with the help of predictive models for the most effective treatment regimens within a patient's individual genetic make-up. In more recent work, combining genomic and clinical data, AI methods have shown better performance in predicting therapeutic outcome than previous single-omics approaches, with the potential for decreasing toxicities and increasing efficacy. Zahra, M. A., Al-Taher, A., Alquhaidan, (2024). Nevertheless, there are some obstacles; for instance, AI models cannot be simply applied into clinical practice since it has been proven that these AI-based tools must be trained and tested on a various population due to the potential discrepancy of performance between datasets (Adir, O., Poley, M., Chen, G., Froim, S., 2020). This pilot study aims to meet these challenges by testing the feasibility of AI in assimilating genomic data into decision support for drug choice in chronic diseases. The study will thus enroll a sample of patients who will have specific DNA sequencing performed on respective genes, which are translated to be involved in drug metabolism, to determine if AI can forecast treatment response and individualize drug prescriptions. Blasiak, A., Khong, J., & Kee, T. (2020). Their purpose is to enrich the current and future body of literature on the topic of integrating artificial intelligence into pharmacogenomics to bring more information and knowledge from the genomic area closer to application in personalized medicine.

Figure No.01: Pilot study: Integration Genomic Data with AI to Optimize Drug Therapy



AI in Drug Discovery

AI is transforming drug discovery as a process because taking a new molecule from the experimental stage to the pharmacy requires resources that take time and money to come together. Drug discovery was traditionally a lengthy and expensive affair, which might take up to 15 years to find a new drug along with about a billion dollars. Blanco-Gonzalez, A., (2023 Due to the development of AI and advanced ML techniques, it becomes possible to explore large datasets related to genetic and biochemical properties and select potential drug targets, as well as predict compound activities and find opportunities to optimize clinical trials. These innovations help the pharma to search for new chemical directions and expedite drug design and development; some of the AI-predicted drug candidates are in preclinical stages within months. Mak, K. K., Wong, Y. H., & Pichika, M. R. (2024).Generic models allow designing new molecules based on the available information on chemical structures. This capability does not only accelerate the drug discovery process but also helps one discover molecules that might have been left out using other techniques. Drug discovery benefits from AI in the form of drug repurposing: drugs are studied to find more uses for them, providing a faster way to address emerging diseases. Deng, J., Yang, Z., Ojima, I., Samaras, D., & Wang, F. (2022). there are drawbacks here. Basic and inclusive data is required for building accurate AI models; however, such data could be limited or heterogenous. AI acted as a 'black box' in which it is not clear how and why the decisions are made; it has ethical and regulatory issues. In order to mitigate this, both the manufacturers of drugs as well as the regulating bodies are trying to enhance data quality, report on the methods used, and improve the interpretability of AI's actions in the sphere of drug discovery so that the usage of the concept is as good as it is moral. David, L., (2020).

Figure No.02: Drug Discovery and Development Timeline with Success Rate



Objectives

This pilot study aims to explore the feasibility of integrating genomic data with AI algorithms to optimize personalized drug therapy. The primary objectives of this research are as follows:

1. To assess how accurately AI models can predict drug efficacy based on patients' genomic data, specifically targeting gene-specific polymorphisms that influence drug metabolism and response.
2. To determine the extent to which AI-guided treatment regimens can reduce the incidence of adverse reactions by selecting optimal drug types and dosages tailored to the patient's genetic profile.
3. To identify genetic markers that most significantly impact drug metabolism and efficacy, and to evaluate how AI can assist in recognizing these markers within complex genomic datasets.
4. To examine patient-reported experiences and outcomes with AI-recommended treatments, including overall satisfaction, reduced side effects, and perceived efficacy, to determine the potential of AI-based approaches for broader clinical applications.
5. To provide foundational data and insights that support the potential of larger-scale studies, helping to pave the way for integrating AI-based genomic analysis in personalized medicine on a broader scale.

Methodology

Study Design

The present work is a pilot one that used a prospective study design to evaluate the possibilities of applying the AI tool to analyze the genomic information of 50 chronic disease patients to improve the drug therapy. The study collects blood samples for the specific sequencing of certain genes and clinical information, and thanks to artificial intelligence, it is possible to determine in advance drug effectiveness and minimize side effects based on a person's genetics. Treatment plans produced through AI are reviewed by clinicians for optimization of the current treatment protocols, focusing on the adverse reactions of the treatments and the results in terms of the extent of improvement or worsening of the patient's condition. AI prediction results evaluated against the outcomes of traditional pharmacogenomics treatments to evaluate the efficiency of AI application, laying the groundwork for future investigations of pharmacogenomics with AI integration.

Genomic Sequencing and Its Role in Personalized Medicine

Pharmacogenomic sequencing, especially when applied to targeted loci, regulates drug metabolism and has become paramount in personalizing patient medicine. This approach is known as pharmacogenomics and is concerned with learning how genetic characteristics determine a patient's reaction to medications, primarily concerning genes related to drug metabolism, transport, and effectiveness. Rabbani, B., (2016).Pharmacogenetic-related genes involved in drug metabolism involve CYP2D6, CYP2C9, and CYP3A4 genes that are of paramount importance in the metabolism of many human drugs Offit, K. (2011).These are known to cause the differences in the metabolizers that determine the effectiveness of a drug or the probability of its negative side effects occurring in the body. Through studying these markers, one can define polymorphisms genetic variations altering enzyme activity rates, which help physicians determine which medications will benefit or harm the patient Tremblay, J., & Hamet, P. (2013). The above information is then sent to other AI algorithms to determine the likely best drug regimens. This integration of genomics with AI helps provide better therapeutic application with fewer side effects to let the efficiency of the treatments thrive better Janitz, M. (Ed.). (2011). AI analyze large genomic datasets and expose hidden patterns of genetic markers that could not be determined by traditional studying of people's genomes; it contributes to the development of personalized medicine. This combines genomic data with AI with the hope of enhancing targeted drug treatment and bringing safer, more efficient quality to precision medicine. Ginsburg, G. S., & Willard, H. F. (Eds.). (2009).

Figure No.02: Impact of Key Gene Polymorphisms on Drug Metabolism



The figure below depicts how genetic polymorphisms in important five genes, namely CYP2D6, CYP2C9, CYP3A4, TPMT, and SLCO1B1, affect drug metabolism measured on a percentage basis. Of these, CYP2D6 is the most affected, with 70% primarily responsible for the metabolism of a large share of drugs prescribed today; where genetic variations result in profound differences in drug efficacy and toxicity, CYP2D6 is essential for pharmacogenomics drugs. CYP2C9 is next with a 60% influence and includes drugs such as anticoagulants and anti-inflammatories, polymorphism of which results in changes in drug activity patterns and the therapeutic outcome. Although genetic polymorphisms have significant effects on drug metabolism and levels in the bloodstream with a 50% efficacy, CYP3A4 metabolizes many medications, including steroids and immunosuppressants. The gene TPMT is expressed at 40% and is involved in the metabolism of chemotherapy and immune therapy drugs, altering patient responses based on the variation of the gene, making dose regulation critical. Last, the SLCO1B1 gene, which represents 30% of the population, represents an OATP family that alters transport rather than metabolism of drugs and food components, where polymorphism results in variability of drug absorption and distribution, which affects statins efficiency and side effects. In brief, the chart depicts how variations of these genes affect the drugs metabolism, and therefore, personalized medicine enables the choice of

drugs and their doses that correspond to a patient's genetic makeup, thus minimizing the side effects while improving the efficacy of the treatments.

Integrating Genomic Data with AI Algorithms to Optimize Personalized Drug Therapy:

Tailored medical decisions, treatments, practices, and products are what the concept or field of personalized medicine is founded upon. An inherent part of this approach is to combine the information from genomic data, which reveals the patient's genetic predispositions, and AI, which can analyze vast amounts of data for any correlations. Taherdoost, H., & Ghofrani, A. (2024). This integration offers a lot of potential in the improvement of pharmacotherapy by identifying the effect of genetic differences on the pharmacological outcomes. Genomic information includes data concerning an individual's entire genetic code and genes that may influence how drugs act within the body. Several studies have recognized that genetic variations in drug-metabolizing genes, including CYP2D6, CYP2C9, and SLCO1B1, are responsible for interpatient variability. For example, polymorphisms in the CYP2D6 enzyme can divide people as poor, intermediate, extensive, or ultra-fast metabolizers, which results in the effectiveness and safety of drugs metabolized through this pathway. Tsigelny, I. F. (2019). AI Algorithms in Drug Therapy Optimization: Artificial intelligence algorithms can identify pattern information from high-dimensional genomic data sets to peruse for drug therapy. Here are several categories of algorithms employed in this context: Such algorithms work from trained samples with known results on the treatment (outcomes such as drug responsiveness). There is a range of methods, like Random Forests and Support Vector Machines (SVM), that can be applied to predict the efficacy of the drug depending on genetic markers. Random forests can readily analyze the high-dimensional genomic data and supply a more reliable approach to ascertain the critical genomic loci engaged in the determination of drug response. CNNs are especially good at modeling hierarchy and thus are appropriate for multi-dimensional data, which is the case with genomics. CNNs are able to identify gene expression or variance in order to estimate the response of a specific patient to a certain therapy. Xu, J., Yang, (2019). They are good at distinguishing correlations in a large set of data, which is essential for comprehending a polyfactorial effect on the metabolism of drugs. This approach incorporates lower-level algorithms that believe data regarding the optimal action and then learn precisely how to attain that result utilizing trial-and-error feedback in the form of a reward. In the context of personalized medicine, reinforcement learning can perform the real-time modification of treatment strategies and even dosages of medications according to the genotypic and phenotypic reactions of a patient. Noorain, Srivastava, V., Parveen, B., & Parveen, R. (2023).Deep Q-Networks can be used for keeping dynamic treatment regulation, patient safety, and reliability of the treatment procedures. Oluwaseyi, J. (2024). Implementation of genomic data and AI solutions entails rigorous data processing procedures. The following steps are typically involved: Genomic data is required to be cleaned and normalized to bring them on the same scale so as to make them incorporated in various datasets. This step may involve dealing with missing values, transforming categorical variables, and normalizing numbers. Jain, N., Nagaich, U., Pandey, M., Chellappan, D. K., & Dua, K. (2022).It is important to identify that many genetic variants should be related to drug responses. Supervised learning models can suggest which genetic polymorphism is meaningful in biological settings as a feature selection approach. Following training the models on data, several validation techniques (e.g., k-fold cross-validation) check on the reliability of their prediction of drug responses. Schork, N. J. (2019). Previous findings show that incorporating genomic information improves the performance of AI systems that can predict the best drug therapy plans. For instance, comprehensive studies to compare the effectiveness of conventional treatment with therapeutic use of multiple medications where dosing is done according to genetic profiles indicate positive and significant improvement in the quality of treatment and a reduced number of side effects. Serrano, D. R., Luciano, (2024). The application of genomic information poses a question about privacy that requires strict measures of data protection impacted with consent. Tong, L., Shi, W., Isgut, (2023). Generalizability of Models: Hypotheses underlying the models have to be verified for different populations to learn how useful and efficient the models under consideration are in terms of functioning with different communities. The addition of genomic data to the mix and feeding it into AI algorithms is a revolutionary opportunity when it comes to treating patients with optimized drug therapy. However, as more research is conducted in this field, there must be more combinations of more intricate algorithms and more extensive datasets to enhance the development of better patient care models. Tong, L., Shi, (2023).

Predictive Analytics and Personalized Genetics

Predictive analytics is an umbrella term for analytical methods that, when used with the aim of individualized genetics, forecast a patient's future state of health while providing the best course of therapy. The incorporation of genetic data with state-of-the-art analysis tools would help the health care management in understanding and forecasting the disease status and therapeutic options. Raparthi, M. (2022). Application of Genomic Data in Predictive Analytics Genomic data refers to information concerning an individual's entire DNA makeup or sequence pertaining to the variance in drug metabolism, disease, and overall health risk. Combination of this data with the predictive analysis enables one to find out relations between the variations in the gene and the occurrence of the disease, and therefore, developing ways of personalized medicine. Yadav, S., MP, S., & Yadav, D. K. (2023,Being an intelligent technique, artificial intelligence (AI) is favorable for making various analyses of large genomic datasets. Random Forests, SVMs, and CNNs, which constitute current machine learning techniques, can recognize patterns and foresee reactions to treatments based on genetics. Suwinski, P., Ong, C., & H. S. (2019). These algorithms improve the knowledge on how genetic differences translate to differential responses to drugs, hence better and safer pharmacotherapy regimens. Applications in Pharmacogenomics is a branch of pharmacology that addresses the concept of drug disposition and response and is divided into two categories. Polymorphisms in drug-metabolizing genes such as CYP2D6, CYP2C9, and SLCO1B1 greatly impact drug metabolism and individual responses to treatment plans. Hassan, M., Awan, F. M. (2022). From these genetic factors, it is possible to build predictive models that will help improve the efficacy of drugs and reduce side effects. Future issues and recommendations There are several issues involved while using the predictive analytic and genetic platforms, the major being the ethical issue of privacy and security of data. Safety of the genomic information and confidentiality are important features that guarantee patient compliance and compliance with the set Code of Regulations. Ibrahim, M. S., & Saber, S. (2023). In addition, another implication of biased samples is that the validity of estimating modeled equations on populations of different demographics requires reconsideration to guarantee appropriate health care for all Prabhod, K. J. (2024). Predictive analytics and personalized genetics make up a compelling business model that is changing the course of healthcare. However, further research and progress are required to build stable and reliable models that may be useful as tools for a wider spectrum of patients.

Table No.02: fictional patient data related to personalized genetics and predictive analytics

Patient ID	Age	Gender	Genetic Variant	Drug Response	Notes
1	34	Male	Poor Metabolizer	Low efficacy	Alternative medication needed
2	28	Female	Extensive Metabolizer	High efficacy	Standard dosage effective
3	45	Male	Intermediate Metabolizer	Moderate efficacy	Monitor for side effects
4	60	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust dosage accordingly
5	22	Male	Poor Metabolizer	Low efficacy	Consider genetic counseling
6	38	Female	Extensive Metabolizer	High efficacy	Standard dosage effective
7	50	Male	Intermediate Metabolizer	Moderate efficacy	Monitor closely
8	29	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust dosage accordingly
9	41	Male	Poor Metabolizer	Low efficacy	Alternative therapy recommended

10	35	Female	Extensive Metabolizer	High efficacy	Standard dosage effective
11	55	Male	Intermediate Metabolizer	Moderate efficacy	Caution advised
12	47	Female	Ultra-Fast Metabolizer	Very high efficacy	Monitor for interactions
13	26	Male	Poor Metabolizer	Low efficacy	Genetic variant counseling
14	31	Female	Extensive Metabolizer	High efficacy	Regular follow-ups needed
15	39	Male	Intermediate Metabolizer	Moderate efficacy	Assess for side effects
16	42	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust dosage accordingly
17	33	Male	Poor Metabolizer	Low efficacy	Consider alternative therapy
18	28	Female	Extensive Metabolizer	High efficacy	Standard therapy effective
19	48	Male	Intermediate Metabolizer	Moderate efficacy	Monitor drug interactions
20	52	Female	Ultra-Fast Metabolizer	Very high efficacy	Increased monitoring needed
21	30	Male	Poor Metabolizer	Low efficacy	Alternative treatment suggested
22	37	Female	Extensive Metabolizer	High efficacy	Standard dosing effective
23	44	Male	Intermediate Metabolizer	Moderate efficacy	Caution advised
24	59	Female	Ultra-Fast Metabolizer	Very high efficacy	Dosage adjustment needed
25	25	Male	Poor Metabolizer	Low efficacy	Monitor for effectiveness
26	36	Female	Extensive Metabolizer	High efficacy	Regular assessments
27	40	Male	Intermediate Metabolizer	Moderate efficacy	Monitor closely
28	51	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust treatment accordingly
29	23	Male	Poor Metabolizer	Low efficacy	Discuss genetic factors
30	34	Female	Extensive Metabolizer	High efficacy	Follow standard protocols
31	46	Male	Intermediate Metabolizer	Moderate efficacy	Evaluate side effects
32	53	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust based on response

33	29	Male	Poor Metabolizer	Low efficacy	Consider alternative therapy
34	39	Female	Extensive Metabolizer	High efficacy	Monitor regularly
35	41	Male	Intermediate Metabolizer	Moderate efficacy	Caution required
36	49	Female	Ultra-Fast Metabolizer	Very high efficacy	Increase monitoring
37	31	Male	Poor Metabolizer	Low efficacy	Genetic counseling advised
38	44	Female	Extensive Metabolizer	High efficacy	Standard dose effective
39	35	Male	Intermediate Metabolizer	Moderate efficacy	Monitor for side effects
40	56	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust treatment needed
41	27	Male	Poor Metabolizer	Low efficacy	Discuss options
42	38	Female	Extensive Metabolizer	High efficacy	Regular follow-ups needed
43	45	Male	Intermediate Metabolizer	Moderate efficacy	Assess for interactions
44	58	Female	Ultra-Fast Metabolizer	Very high efficacy	Dosage adjustment needed
45	24	Male	Poor Metabolizer	Low efficacy	Alternative therapy suggested
46	32	Female	Extensive Metabolizer	High efficacy	Standard therapy effective
47	48	Male	Intermediate Metabolizer	Moderate efficacy	Monitor closely
48	54	Female	Ultra-Fast Metabolizer	Very high efficacy	Adjust dosage accordingly
49	26	Male	Poor Metabolizer	Low efficacy	Consider genetic counseling
50	37	Female	Extensive Metabolizer	High efficacy	Regular assessments needed

Machine Learning in Drug Discovery

Machine learning-based methods have turned out to be promising weapons in the discovery processes of new drugs, capable of providing novel approaches to virtual screening, target identification, and lead optimization. Dara, S. (2022). Application of big data and machine learning enables chemists to quickly draw connections between chemical compounds, biological active targets, and molecular interactions, all while identifying and providing more accurate and efficient potential drug liabilities. Vamathevan, J., Clark (2019).

Virtual Screening in Drug Discovery

Virtual screening could be described as the use of computational methods to screen out large libraries of compounds in the search of drug candidates. It is one of the steps practiced at the initial stages of drug discovery or development. Reddy, A. S., Pati, S. P. (2007). Virtual screening techniques spanned only molecular docking and pharmacophore modeling and employed rigid structures of the ligand-target interaction patterns, accompanied by rather low predictive abilities. Current machine learning methodologies provide a more sound and adaptable strategy to virtual screening and enable the examination of numerous chemical attributes as well as the forecast of ligand-target interaction with higher accuracy. Lionta, E. (2014). The major strength of machine learning-based virtual screening is its ability to implicitly model relationships in large databases of chemical and biological targets. The effectiveness of a machine learning model is determined by the annotated dataset that the model was trained with in terms of ligand-target interactions. This can then be targeted with a machine learning algorithm to uncover any structural motifs or physicochemical properties that are strong indicators of binding affinity and, in turn, create an accurate prediction of ligand-target interaction in the novel compounds. Hou, T., & Xu, X. (2004).

Lead Optimization in Drug Discovery

The systematic process of lead optimization in lead identification makes use of machine learning algorithms in order to predict the biological activity and other drug-like properties of analogs of new chemical compounds. de Souza Neto, L. R., Moreira-Filho (2020). The employment of machine learning-based lead optimization allows one to improve the outcomes of discovering the chemical structures with the biological activities that define the structure-activity relationships (SARs) of the target interactions. Incorporating supervised learning into the design process then allows for the development of predictive models of compound activity that correlate signaling differences with desired biological effects while providing features and substructures that can be used to guide the design of new molecules and reduce the dependence on expensive and time-consuming experimental testing. Kenakin, T. (2003).

Table No.03:Summary of software platforms that utilize AI techniques, such as deep learning, predictive modeling, and virtual screening, to accelerate various stages of the drug discovery and drug development process.

Platform Name	Description	AI Techniques Used	Key Features
DeepMind AlphaFold	Predicts protein structures from amino acid sequences.	Deep Learning	Accurate 3D structure prediction; aids in drug target identification.
IBM Watson for Drug Discovery	Analyzes scientific literature and data to identify potential drug candidates.	Natural Language Processing, Machine Learning	Knowledge graph for drug interactions; genomic data analysis.
Atomwise	Uses AI to predict binding of small molecules to proteins for drug discovery.	Deep Learning	Virtual screening of compounds; high-throughput screening simulations.

Insilico Medicine	Focuses on drug discovery and development using AI-driven platforms.	Deep Learning, Reinforcement Learning	Predictive modeling for drug efficacy; biomarker discovery.
Benevolent AI	Leverages AI to mine scientific literature and data for drug development insights.	Machine Learning	Data-driven drug discovery; identifies novel drug candidates.
Schrodinger	Provides software for molecular modeling and simulations in drug design.	Machine Learning, Quantum Mechanics	High-performance modeling; virtual screening capabilities.
CureMetrix	Uses AI for diagnostic imaging analysis in drug efficacy studies.	Deep Learning	AI-driven analysis of medical images; assists in assessing treatment outcomes.
CureMetrix	An AI platform focusing on molecular dynamics simulations and predictive modeling.	Machine Learning, Molecular Dynamics	Acceleration of drug binding simulations; predictive modeling of drug interactions.
XtalPi	Utilizes AI to optimize drug formulations and predict crystallization outcomes.	Machine Learning	Predicts solid-state behavior; optimizes drug formulations.
Recursion Pharmaceuticals	Combines AI with biology to uncover new drug targets and develop therapeutics.	Deep Learning, Predictive Modeling	High-throughput screening; patient-centric drug discovery.
Novo Nordisk's AI Platform	AI-based platform to improve drug discovery and development processes.	Machine Learning	Integrated AI for data analysis across drug discovery stages.

AI in Predictive Modeling and Personalized Medicine and Formulation

Artificial intelligence and specifically deep artificial methods such as support vector machines, random forests, and neural networks are indispensable to the prediction of drug responses. In more detail, they have evolved into truly valuable resources for determining the way one patient will react to a particular drug relative to the general physiology of every human being. Serrano, D. R. (2024). This can be integrated because of the large biomedical data base from genomics, proteomics, and metabolomics to determine biomarkers that are related to drug efficacy and safety. Through these models, clinical decisions to determine which medication should be given to a patient can be made with minimal effects from adverse effects, thus leading to improved treatment outcomes. Prabhod, K. J. (2023). The themes of the treatment regimens' optimization be incorporated into machine learning tools. Over time, AI algorithms may ascertain dose preparation regimens from the responses given by patients and immediately adapt to greater effectiveness accompanied by reduced adverse effects. This has been used to model the frequency and timing of chemotherapy cycles in chemotherapy regimens for cancer diseases. AI can combine EHR, CT, and RWE to create patient-specific therapeutic management plans. These are not rigid activity plans like those that are usually fond of written protocols but are revised as the patient information changes; they are more flexible and adaptable. AI approach based on coevolutionary neural networks with histopathological examination of tissue slides and clinicopathological characteristics of patients and their response to checkpoint immunotherapy in the advanced melanoma patient specimen. It is important to identify when the current therapy is not beneficial to a given patient in order that clinicians can modify or stop the treatment within a short period. In clinical practice, cancer progression and treatment response are usually assessed from the change in size of the tumor or the appearance of new lesions, which involves a review of the pathology or radiology images. Ali, K. A., Mohin, S. K. (2024).

AI in Formulation and Drug Delivery

Pharmacokinetics, a very important issue of the pharmaceutical industry, has remained a challenge of formulating and delivering drugs. AI is useful to enhance the formulation of the drug; in other traditional methods, it may take lots of time to attempt and reattempt before formulating the right formula, like the nanoparticles and the mechanism of delivering nanoparticles to the targeted body part., ensuring that active ingredients are delivered to the target site in the body with maximum efficiency. Hassanzadeh, (2019). It is possible to accurately forecast the release profile of a medicine from a given formulation, the possibility of developing controlled-release formulations of medicines that will enable a steady release of the medicine in the bloodstream, Understanding how these systems will perform in the body can pave the way for the advanced drug delivery technologies that are able to address the current deficiencies. Vora, L. K., Gholap, (2023).



Figure No.02:AI predictive modeling in personalized medicines, drug formulation, drug–excipient compatibility,

drug solubility, bioavailability, nanomedicines, and microfluidics.





Optimization of Excipients and Drug Combinations and Compatibility

These ingredients, so-called excipients, influence the stability, the bioavailability, and the therapeutic effect of a pharmaceutical product. Historically, the selection of the right blend of excipients requires lots of trial and error. Most of the machine learning approaches offer the opportunity to determine the best combinations of the excipients from big data to improve drug performance. When the right data set is created, the AI models can be used to accurately forecast the right amounts of excipients that need to be added to achieve the right disintegration and dissolution time. The use of 3D-printed medicines involves logical data on merging 3D printers, AI and personalized medicines, multi-faced fabrication of pharmaceuticals, and drug delivery systems. The use of 3D printing in pharmaceuticals can be highly versatile than conventional systems but is highly challenging to implement in clinical practice due to fabrication complexity and fine dosing control without compromising drug degradation. AI algorithms can tailor the design and formulation of 3D-printed dosage forms to individual patient factors, such as age, weight, and medical history, resulting in customized drug therapies. These dosage forms can be modeled and designed using the predictions AI made after analyzing vast amounts of data on the behavior of these dosage forms. In the fastest possible time, new prototypes can be developed and drug release profiles, dosage strengths, and geometries optimized for. Moreover, it enables us to estimate and solve possible manufacturing issues by adjusting print settings and maintaining the product's quality. Real-time data feedback systems where AI is built from such structure help advance 3D-printing outcomes as the model adapts and learns from actual data, thus increasing accuracy, reproducibility, and scalability.

AI in Designing Nanocarriers and Targeted Delivery Systems

Nanomedicines need nanocarriers, including liposomes, nanoparticles, dendrimers, polyplexes, transferosomes, nano self-emulsifying systems, and others. Nanocarriers are employed with the objective of increasing the concentration of the drug at the targeted site of the body, thereby increasing its efficacy and decreasing its toxicity to other parts of the body. This is important in the case of diseases like cancer or infection or when there is a need to trigger a drug that has poor physicochemical characteristics through biological barriers like the blood-brain barrier, skin, or intestinal wall. triggering drugs with a poorly physicochemical profile through different physiological barriers such as the blood-brain barrier, stratum corneum, or intestinal epithelium Designing efficient nanomedicine for drug delivery systems is challenging but takes into account the range of tunable parameters, including the size and geometry of nanoparticles and their surface alteration and composition, as these aspects directly influence circulation time, cellular uptake, and biodistribution profiles. For instance, circulation time is longer in a smaller size and possesses high penetration through the deeper tissues, and similarly, the rod-shaped or elongated particles are taken up actively compared to spherical ones. Current methods of designing and optimizing nanomedicines include time-consuming experimental setup and the utilization of a trial-and-error technique.

Examples of AI Applications in the Pharmaceutical Industry

AI today is at the forefront of the disruption across multiple stages of pharmaceutical manufacture, including identification of the most suitable excipients, identifying the synthesis route, process optimization, drug designing, supply chain management, and intelligent preventive maintenance, to mention just a few. AI has the proven ability to reduce both the cost and time needed from developing therapeutic products, starting from identifying the molecule appropriate for the final drug and up to clinical testing. The application of AI increases hit identification and optimization beyond what would historically be the first round of lead optimization and most basic preclinical assessment. It can be further noted that, when used in the right coordination, the AI solutions can bring efficiency in the drug discovery phase, which may take 3-6 years mostly. In this way, AI can decrease this time to 1 to 2 years through making better predictions about drug efficacy, toxicity, and the right molecular structures. Drug discovery is estimated to make up to 35% of the total cost of developing a new drug, which may cost around $2.8 billion. AI can help design better clinical trials with regard to the identification of patients, supervision of patients, and decreasing the duration and cost of trials. AI shorten the time it takes to perform trials for clinical tests since testing and data analysis can be computerized, which would make the check on patients easier. This has reduced trial length by 15 to 30 percent. AI can reduce the time taken by drugs to transit from Phase I to Phase III, where AI can predict adverse effects and better dosing strategies. amongst others. This has cut the length of trials by 15 to 30 percent. By predicting adverse effects earlier and optimizing dosing strategies, AI can cut down the time it takes for drugs to move from Phase I to Phase III. Of the molecules discovered utilizing AI, earlier results observed have been better than those of molecules that were identified through conventional methods. AI-driven compounds have been successful in Phase 1 trials with a success rate of 80-90% as compared to an industry standard of 40-65%. In Phase 2 trials, molecules identified by AI have an efficacy of approximately 40%, which is in line with efficacy values observed previously. If these trends do extend into phase III/other subsequent phases, the pharmaceutical industry may receive a raise in the probability of a molecule successfully progressing through all clinical phases from 5-10% to 9-18%.

Examples of AI applications in the pharmaceutical industry. Image created using OpenArt.



Table No.05:Applications of AI in the Industrial Manufacturing Process of Medicines and Excipient Selection.

Application	Description	AI Benefits
Synthesis Route Prediction	Predicts optimal pathways for synthesizing drug compounds and intermediates	Reduces time and costs in identifying efficient synthesis pathways
Robotic Synthesis	Uses robots for automated synthesis of compounds in laboratory settings	Increases precision and speeds up high-throughput screening
Drug Design	Assists in creating molecular structures based on target proteins and desired effects	Accelerates discovery of effective drug candidates
Formulation Optimization	Determines ideal drug formulation to maximize stability and effectiveness	Reduces trial-and-error, enhances efficacy and stability

Compound Selection	Analyzes large data sets to identify promising compounds with desired properties	Streamlines candidate selection, saving time and resources
Process Optimization	Optimizes manufacturing steps to increase efficiency and reduce waste	Lowers costs, improves consistency, and reduces environmental impact
Data Analysis	Processes vast amounts of data from experiments and clinical trials	Increases insights and predictive accuracy, improving decision-making
Manufacturing Optimization	Enhances control and monitoring of manufacturing parameters for quality control	Improves yield and consistency in production
Process Development	Supports development of scalable processes for large-scale production	Reduces time to scale-up from lab to commercial production
Excipient Screening	Identifies the best excipients to improve drug delivery and stability	Increases stability, bioavailability, and patient outcomes

Future Perspective and Conclusion

As the technology progresses in the future, one will find deep learning and reinforcement learning used to enhance synthesis routes, excipients, and formulations when developing more formulations. These developments could result in the creation of entirely automated synthesis systems up to individual drug molecule design and construction. AI could create the basis for the so-called "smart drugs," or drugs customized to specific patients' genetic and lifestyle characteristics. Such a strategy will enhance the outcomes of therapies and reduce negative side effects that can be afforded by multiplying factors such as cancer or rare hereditary diseases. It might be further enhanced that AI process monitorization will reach a level of real-time capacity to tweak the manufacturing environment conditions as a means of preserving product quality and minimizing material loss. The future generation of AI systems can therefore forecast and prevent manufacturing problems before they happen, considering data from sensors and machine learning algorithms. It will be easier for the drug-manufacturing regulatory authorities to approve drugs because AI's data analytics will record and validate each phase of the manufacturing process. AI can be seen assisting the transition towards more sustainable processes that are environmentally harmonious by preventing waste, identifying better use of reagents, and green chemistry in

synthesis pathways. The use of artificial intelligence in the manufacturing of medicine and selection of the excipients is enhancing the pharmaceutical industry by enhancing the rate of productivity, precision, and accuracy. The application of AI across the different aspects has been demonstrated to be effective in synthesis route prediction and one-pot synthetic robotic synthesis, excipient selection, and manufacturing process optimization. In this regard, as these technologies progress, there is a certain potential for AI to transform the way of drug development and manufacturing toward faster, safer, and more sustainable ways. AI in pharmaceutical manufacturing shows a world in which individual and flexible medicine, respectively, shorter cycles, and improved environmental aspects are possible. However, achieving these benefits will not be without some challenges. Some of these challenges include data privacy, ethical questions, and most importantly, collaboration between artificial intelligence specialists, pharmacists, and other regulatory agencies.

References:

1. Barrett, J.S.; Oskoui, S.E.; Russell, S.; Borens, A. Digital Research Environment(DRE)-enabled Artificial Intelligence (AI) to facilitate early-stage drug development. Front. Pharmacol. 2023, 14, 1115356.
2. Beis, G.; Serafeim, A.P.; Papasotiriou, I. Data-driven analysis and druggability assessment methods to accelerate the identification of novel cancer targets. Comput. Struct. Biotechnol. J. 2023, 21, 46–57.
3. Benevolent AI Drug Discovery. Available online: https://www.benevolent.com (accessed on 12 August 2024).
4. Bhinder, B.; Gilvary, C.; Madhukar, N.S.; Elemento, O. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov. 2021, 11, 900–915.
5. Bittner, M.I.; Farajnia, S. AI in drug discovery: Applications, opportunities, and challenges. Patterns 2022, 3, 100529.
6. Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: challenges, opportunities, and strategies. *Pharmaceuticals*, *16*(6), 891.
7. Blanco-Gonzalez, A.; Cabezon, A.; Seco-Gonzalez, A.; Conde-Torres, D.; Antelo-Riveiro, P.; Pineiro, A.; Garcia-Fandino, R. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals 2023, 16, 891.
8. Blasiak, A., Khong, J., & Kee, T. (2020). CURATE. AI: optimizing personalized medicine with artificial intelligence. *SLAS TECHNOLOGY: Translating Life Sciences Innovation*, *25*(2), 95-105.
9. Blasiak, A.; Khong, J.; Kee, T. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence. Transl. Life Sci. Innov. 2020, 25, 95–105. [CrossRef]
10. Brinkhaus, H.O.; Rajan, K.; Schaub, J.; Zielesny, A.; Steinbeck, C. Open data and algorithms for open science in AI-driven molecular informatics. Curr. Opin. Struct. Biol. 2023, 79, 102542.
11. Burki, T. Pharma blockchains AI for drug development. Lancet 2019, 393, 2382.
12. Carpenter, K.A.; Huang, X. Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review. Curr. Pharm. Des. 2018, 24, 3347–3358.
13. Carracedo-Reboredo, P.; Linares-Blanco, J.; Rodriguez-Fernandez, N.; Cedron, F.; Novoa, F.J.; Carballal, A.; Maojo, V.; Pazos, A.; Fernandez-Lozano, C. A review on machine learning approaches and trends in drug discovery. Comput. Struct. Biotechnol. J. 2021, 19, 4538–4558.
14. Chang,W.T.; Liu, C.F.; Feng, Y.H.; Liao, C.T.; Wang, J.J.; Chen, Z.C.; Lee, H.C.; Shih, J.Y. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. Arch. Toxicol. 2022, 96, 2731–2737.
15. Chatterjee, A.; Pahari, N.; Prinz, A.; Riegler, M. AI and semantic ontology for personalized activity eCoaching in healthy lifestyle recommendations: A meta-heuristic approach. BMC Med. Inform. Decis. Mak. 2023, 23, 278.
16. Cong, F., Cheung, A. K., & Huang, S. M. A. (2012). Chemical genetics–based target identification in drug discovery. *Annual review of pharmacology and toxicology*, *52*(1), 57-78.
17. Cyclica. Available online: https://cyclicarx.com/science (accessed on 13 August 2024).
18. Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022). Machine learning in drug discovery: a review. *Artificial intelligence review*, *55*(3), 1947-1999.
19. Dara, S.; Dhamercherla, S.; Jadav, S.S.; Babu, C.M.; Ahsan, M.J. Machine Learning in Drug Discovery: A Review. Artif. Intell. Rev. 2022, 55, 1947–1999.

20. David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020). Molecular representations in AI-driven drug discovery: a review and practical guide. *Journal of Cheminformatics*, *12*(1), 56.
21. de Souza Neto, L. R., Moreira-Filho, J. T., Neves, B. J., Maidana, R. L. B. R., Guimarães, A. C. R., Furnham, N., ... & Silva Jr, F. P. (2020). In silico strategies to support fragment-to-lead optimization in drug discovery. *Frontiers in chemistry*, *8*, 93.
22. DeepChem. Available online: https://deepchem.io (accessed on 13 August 2024). 49. Schrödinger's Maestro Platform. Available online: https://www.schrodinger.com/platform/products/maestro (accessed on 13 August 2024).
23. DeepMind's AlphaFold Algorithm. Available online: https://deepmind.google/technologies/alphafold (accessed on 12 August 2024).
24. Deng, J., Yang, Z., Ojima, I., Samaras, D., & Wang, F. (2022). Artificial intelligence in drug discovery: applications and techniques. *Briefings in Bioinformatics*, *23*(1), bbab430.
25. Dercle, L.; Fronheiser, M.; Lu, L.; Du, S.; Hayes, W.; Leung, D.K.; Roy, A.; Wilkerson, J.; Guo, P.; Fojo, A.T.; et al. Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. Clin. Cancer Res. 2020, 26, 2151–2162
26. DGIdb. Available online: https://www.dgidb.org (accessed on 12 August 2024).
27. Efficacy and Safety of REC-2282 in Patients with Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR NF2). Available online: https://clinicaltrials.gov/study/NCT05130866?term=POPLAR&rank=2 (accessed on 12 August 2024).
28. Gallego, V.; Naveiro, R.; Roca, C.; Rios Insua, D.; Campillo, N.E. AI in drug development: A multidisciplinary perspective. Mol. Divers. 2021, 25, 1461–1479.
29. Garbarino, S.; Bragazzi, N.L. Revolutionizing Sleep Health: The Emergence and Impact of Personalized Sleep Medicine. J. Pers. Med. 2024, 14, 598.
30. Gaudelet, T.; Day, B.; Jamasb, A.R.; Soman, J.; Regep, C.; Liu, G.; Hayter, J.B.R.; Vickers, R.; Roberts, C.; Tang, J.; et al. Utilizing graph machine learning within drug discovery and development. Brief. Bioinform. 2021, 22, bbab159.
31. Ginsburg, G. S., & Willard, H. F. (Eds.). (2009). *Essentials of genomic and personalized medicine*. Academic Press.
32. Hao,Y.; Lynch, K.; Fan, P.; Jurtschenko, C.; Cid, M.; Zhao, Z.; Yang, H.S. Development of a Machine Learning Algorithm for Drug Screening Analysis on High-Resolution UPLC-MSE/QTOF Mass Spectrometry. J. Appl. Lab. Med. 2023, 8, 53–66. [CrossRef]
33. Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., ... & Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: A review. *International journal of molecular Sciences*, *23*(9), 4645.
34. Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019). The significance of artificial intelligence in drug delivery system design. *Advanced drug delivery reviews*, *151*, 169-190.
35. Hill, A.; True, J.M.; Jones, C.H. Transforming drug development with synthetic biology and AI. Trends Biotechnol. 2024, 42, 1072–1075.
36. Hong,E.; Jeon, J.; Kim, H.U. Recent development of machine learning models for the prediction of drug-drug interactions. Korean J. Chem. Eng. 2023, 40, 276–285.
37. Hou, T., & Xu, X. (2004). Recent development and application of virtual screening in drug discovery: an overview. *Current pharmaceutical design*, *10*(9), 1011-1033.
38. Ibrahim, M. S., & Saber, S. (2023). Machine learning and predictive analytics: Advancing disease prevention in healthcare. *Journal of Contemporary Healthcare Analytics*, *7*(1), 53-71.
39. Iorio, F.; Knijnenburg, T.A.; Vis, D.J.; Bignell, G.R.; Menden, M.P.; Schubert, M.; Aben, N.; Goncalves, E.; Barthorpe, S.; Lightfoot, H.; et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 2016, 166, 740–754.
40. Jain, N., Nagaich, U., Pandey, M., Chellappan, D. K., & Dua, K. (2022). Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements. *EPMA Journal*, *13*(4), 561-580.
41. Janitz, M. (Ed.). (2011). *Next-generation genome sequencing: towards personalized medicine*. John Wiley & Sons.

42. Johannet, P.; Coudray, N.; Donnelly, D.M.; Jour, G.; Illa-Bochaca, I.; Xia, Y.; Johnson, D.B.; Wheless, L.; Patrinely, J.R.; Nomikou, S.; et al. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clin. Cancer Res. 2021, 27, 131–140. [CrossRef] [PubMed]
43. Kargarandehkordi, A.; Slade, C.; Washington, P. Personalized AI-Driven Real-Time Models to Predict Stress-Induced Blood Pressure Spikes Using Wearable Devices: Proposal for a Prospective Cohort Study. JMIR Res. Protoc. 2024, 13, e55615.
44. Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M. T. (2016). Computational approaches in target identification and drug discovery. *Computational and structural biotechnology journal*, *14*, 177-184.
45. Kenakin, T. (2003). Predicting therapeutic value in the lead optimization phase of drug discovery. *Nature Reviews Drug Discovery*, *2*(6), 429-438.
46. Khansari, N. (2024). AI Machine Learning Improves Personalized Cancer Therapies. *Australasian Medical Journal (Online)*, *17*(2), 1166-1173.
47. Khokhar, S.; Holden, J.; Toomer, C.; Del Parigi, A. Weight Loss with an AI-Powered Digital Platform for Lifestyle Intervention. Obes. Surg. 2024, 34, 1810–1818. [CrossRef]
48. Kontoyianni, M. (2017). Docking and virtual screening in drug discovery. *Proteomics for drug discovery: Methods and protocols*, 255-266.
49. Kuenzi, B.M.; Park, J.; Fong, S.H.; Sanchez, K.S.; Lee, J.; Kreisberg, J.F.; Ma, J.; Ideker, T. Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell 2020, 38, 672–684.e676. [CrossRef]
50. Lam,B.; Catt, M.; Cassidy, S.; Bacardit, J.; Darke, P.; Butterfield, S.; Alshabrawy, O.; Trenell, M.; Missier, P. Using Wearable Activity Trackers to Predict Type 2 Diabetes: Machine Learning-Based Cross-sectional Study of the UK Biobank Accelerometer Cohort. JMIR Diabetes 2021, 6, e23364.
51. Le, N.Q.K.; Tran, T.X.; Nguyen, P.A.; Ho, T.T.; Nguyen, V.N. Recent progress in machine learning approaches for predicting carcinogenicity in drug development. Expert Opin. Drug Metab. Toxicol. 2024, 20, 621–628.
52. Leitner, J.; Chiang, P.H.; Agnihotri, P.; Dey, S. The Effect of an AI-Based, Autonomous, Digital Health Intervention Using Precise Lifestyle Guidance on Blood Pressure in Adults with Hypertension: Single-Arm Nonrandomized Trial. JMIR Cardio 2024, 8, e51916.
53. Lionta, E., Spyrou, G., K Vassilatis, D., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Current topics in medicinal chemistry*, *14*(16), 1923-1938.
54. Liu, D.; Schilling, B.; Liu, D.; Sucker, A.; Livingstone, E.; Jerby-Arnon, L.; Zimmer, L.; Gutzmer, R.; Satzger, I.; Loquai, C.; et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 2019, 25, 1916–1927.
55. Liu, Q.; Zhu, H.; Liu, C.; Jean, D.; Huang, S.M.; ElZarrad, M.K.; Blumenthal, G.; Wang, Y. Application of Machine Learning in Drug Development and Regulation: Current Status and Future Potential. Clin. Pharmacol. Ther. 2020, 107, 726–729.
56. Liu, X.; Read, S.J. Development of a multivariate prediction model for antidepressant resistant depression using reward-related predictors. Front. Psychiatry 2024, 15, 1349576.
57. Lloyd, L. AI for drug discovery. Nat. Rev. Urol. 2024, 21, 517.
58. Luo, Y.; Peng, J.; Ma, J. Next Decade's AI-Based Drug Development Features Tight Integration of Data and Computation. Heal. Data Sci. 2022, 2022, 9816939.
59. Mak, K. K., Wong, Y. H., & Pichika, M. R. (2024). Artificial intelligence in drug discovery and development. *Drug discovery and evaluation: safety and pharmacokinetic assays*, 1461-1498.
60. Marques, L.; Costa, B.; Pereira, M.; Silva, A.; Santos, J.; Saldanha, L.; Silva, I.; Magalhaes, P.; Schmidt, S.; Vale, N. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics 2024, 16, 332. [CrossRef]
61. Mshani, I.H.; Jackson, F.M.; Mwanga, R.Y.; Kweyamba, P.A.; Mwanga, E.P.; Tambwe, M.M.; Hofer, L.M.; Siria, D.J.; Gonzalez Jimenez, M.; Wynne, K.; et al. Screening of malaria infections in human blood samples with varying parasite densities and anaemic conditions using AI-Powered mid-infrared spectroscopy. Malar. J. 2024, 23, 188.
62. Mukherjee, D.; Roy, D.; Thakur, S. Transforming Cancer Care: The Impact of AI-Driven Strategies. Curr. Cancer Drug Targets 2024, 24, 1–4.

63. Niazi, S.K. The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug Des. Dev. Ther. 2023, 17, 2691–2725.
64. Noorain, Srivastava, V., Parveen, B., & Parveen, R. (2023). Artificial intelligence in drug formulation and development: applications and future prospects. *Current drug metabolism*, *24*(9), 622-634.
65. Offit, K. (2011). Personalized medicine: new genomics, old lessons. *Human genetics*, *130*, 3-14.
66. Oluwaseyi, J. (2024). Personalized Medicine: Leveraging AI to Tailor Pharmacotherapy.
67. Parvatikar, P.P.; Patil, S.; Khaparkhuntikar, K.; Patil, S.; Singh, P.K.; Sahana, R.; Kulkarni, R.V.; Raghu, A.V. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antivir. Res. 2023, 220, 105740. [CrossRef]
68. Prabhod, K. J. (2023). Leveraging Generative AI for Personalized Medicine: Applications in Drug Discovery and Development. *Journal of AI-Assisted Scientific Discovery*, *3*(1), 392-434.
69. Prabhod, K. J. (2024). Leveraging Generative AI and Foundation Models for Personalized Healthcare: Predictive Analytics and Custom Treatment Plans Using Deep Learning Algorithms. *Journal of AI in Healthcare and Medicine*, *4*(1), 1-23.
70. Qian, X., Liao, J., & Fang, Y. (2024). Advances in Personalized Medicine: Integrating Genomics and Precision Therapeutics. *Medicine Insights*, *1*(3), 1-7.
71. Quazi, S. (2022). Artificial intelligence and machine learning in precision and genomic medicine. *Medical Oncology*, *39*(8), 120.
72. Raparthi, M., Maruthi, S., Reddy, S. R. B., Thunki, P., Ravichandran, P., & Dodda, S. B. (2022). Data Science in Healthcare Leveraging AI for Predictive Analytics and Personalized Patient Care. *Journal of AI in Healthcare and Medicine*, *2*(2), 1-11.
73. Recursion. AI Algorithm. Available online: https://www.recursion.com (accessed on 12 August 2024).
74. Reda, C.; Kaufmann, E.; Delahaye-Duriez, A. Machine learning applications in drug development. Comput. Struct. Biotechnol. J. 2020, 18, 241–252.
75. Reddy, A. S., Pati, S. P., Kumar, P. P., Pradeep, H. N., & Sastry, G. N. (2007). Virtual screening in drug discovery-a computational perspective. *Current Protein and Peptide Science*, *8*(4), 329-351.
76. Rehan, H. (2024). Advancing Cancer Treatment with AI-Driven Personalized Medicine and Cloud-Based Data Integration. *Journal of Machine Learning in Pharmaceutical Research*, *4*(2), 1-40.
77. Rodrigues, T.; Bernardes, G.J.L. Machine learning for target discovery in drug development. Curr. Opin. Chem. Biol. 2020, 56, 16–22.
78. Sarkar, C.; Das, B.; Rawat, V.S.; Wahlang, J.B.; Nongpiur, A.; Tiewsoh, I.; Lyngdoh, N.M.; Das, D.; Bidarolli, M.; Sony, H.T. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int. J. Mol. Sci. 2023, 24, 2026.
79. Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. *Nature chemical biology*, *9*(4), 232-240.
80. Schneider, P.; Walters, W.P.; Plowright, A.T.; Sieroka, N.; Listgarten, J.; Goodnow, R.A., Jr.; Fisher, J.; Jansen, J.M.; Duca, J.S.; Rush, T.S.; et al. Rethinking drug design in the artificial intelligence era. Nat. Rev. Drug Discov. 2020, 19, 353–364.
81. Schork, N. J. (2019). Artificial intelligence and personalized medicine. *Precision medicine in Cancer therapy*, 265-283.
82. Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. *Pharmaceutics*, *16*(10), 1328.
83. Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. *Pharmaceutics*, *16*(10), 1328.
84. Sexton, J.Z.; Fursmidt, R.; O'Meara, M.J.; Omta, W.; Rao, A.; Egan, D.A.; Haney, S.A. Machine Learning and Assay Development for Image-based Phenotypic Profiling of Drug Treatments. In Assay Guidance Manual; Markossian, S., Grossman, A., Arkin, M., Auld, D., Austin, C., Baell, J., Brimacombe, K., Chung, T.D.Y., Coussens, N.P., Dahlin, J.L., et al., Eds.; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, USA, 2004.

85. Shams, A. (2024). Leveraging State-of-the-Art AI Algorithms in Personalized Oncology: From Transcriptomics to Treatment. *Diagnostics*, *14*(19), 2174.
86. Sheu, Y.H.; Magdamo, C.; Miller, M.; Das, S.; Blacker, D.; Smoller, J.W. AI-assisted prediction of differential response to antidepressant classes using electronic health records. NPJ Digit. Med. 2023, 6, 73.
87. Siddiqui, G.A.; Stebani, J.A.; Wragg, D.; Koutsourelakis, P.S.; Casini, A.; Gagliardi, A. Application of Machine Learning Algorithms to Metadynamics for the Elucidation of the Binding Modes and Free Energy Landscape of Drug/Target Interactions: A Case Study. Chemistry 2023, 29, e202302375.
88. Stafford, K.A.; Anderson, B.M.; Sorenson, J.; van den Bedem, H. AtomNet Pose Ranker: Enriching Ligand Pose Quality for Dynamic Proteins in Virtual High-Throughput Screens. J. Chem. Inf. Model. 2022, 62, 1178–1189. Atomwise. Available online: https://www.atomwise.com (accessed on 12 August 2024).
89. Stankoski, S.; Jordan, M.; Gjoreski, H.; Lustrek, M. Smartwatch-Based Eating Detection: Data Selection for Machine Learning from Imbalanced Data with Imperfect Labels. Sensors 2021, 21, 1902.
90. Suwinski, P., Ong, C., Ling, M. H., Poh, Y. M., Khan, A. M., & Ong, H. S. (2019). Advancing personalized medicine through the application of whole exome sequencing and big data analytics. *Frontiers in genetics*, *10*, 49.
91. Taherdoost, H., & Ghofrani, A. (2024). AI and the Evolution of Personalized Medicine in Pharmacogenomics. *Intelligent Pharmacy*.
92. Tiwari, S. K., Singh, V., & Kushwaha, S. K. (2024). A REVIEW ON: THE IMPACT OF ARTIFICIAL INTELLIGENCE IN FORMULATION DEVELOPMENT.
93. Tong, L., Shi, W., Isgut, M., Zhong, Y., Lais, P., Gloster, L., ... & Wang, M. D. (2023). Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. *IEEE Reviews in Biomedical Engineering*.
94. Tong, L., Shi, W., Isgut, M., Zhong, Y., Lais, P., Gloster, L., ... & Wang, M. D. (2023). Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. *IEEE Reviews in Biomedical Engineering*.
95. Tremblay, J., & Hamet, P. (2013). Role of genomics on the path to personalized medicine. *Metabolism*, *62*, S2-S5.
96. Tsigelny, I. F. (2019). Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*, *20*(4), 1434-1448.
97. Tsigelny, I. F. (2019). Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*, *20*(4), 1434-1448.
98. Tsigelny, I. F. (2019). Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*, *20*(4), 1434-1448.
99. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. *Nature reviews Drug discovery*, *18*(6), 463-477.
100. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916.
101. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916.
102. XtalPi. Available online: https://www.xtalpi.com/en (accessed on 13 August 2024).
103. Xu, J., Yang, P., Xue, S., Sharma, B., Sanchez-Martin, M., Wang, F., ... & Parikh, B. (2019). Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. *Human genetics*, *138*(2), 109-124.
104. Yadalam, P.K.; Anegundi, R.V.; Ramadoss, R.; Shrivastava, D.; Almufarrij, R.A.S.; Srivastava, K.C. AI-based 3D-QSAR model of FDA-approved repurposed drugs for inhibiting sclerostin. Technol. Health. Care 2024, 32, 3007–3019. [CrossRef] [PubMed]
105. Yadav, S., MP, S., & Yadav, D. K. (2023, December). Predictive Analytics and AI for Personalized Treatment Plans in Genetic Heart Diseases. In *2023 IEEE International Conference on ICT in Business Industry & Government (ICTBIG)* (pp. 1-7). IEEE.
106. Yoon,J.T.; Lee, K.M.; Oh, J.H.; Kim, H.G.; Jeong, J.W. Insights and Considerations in Development and Performance Evaluation of Generative Adversarial Networks (GANs): What Radiologists Need to Know. Diagnostics 2024, 14, 1756. [CrossRef] [PubMed]

107. You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., ... & Zhang, L. (2022). Artificial intelligence in cancer target identification and drug discovery. *Signal Transduction and Targeted Therapy*, *7*(1), 156.
108. Yuan, H.Y.; Tong, X.F.; Ren, Y.Y.; Li, Y.Y.; Wang, X.L.; Chen, L.L.; Chen, S.D.; Jin, X.Z.; Wang, X.D.; Targher, G.; et al. AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study. Liver Int. 2024, 44, 10
109. Zahra, M. A., Al-Taher, A., Alquhaidan, M., Hussain, T., Ismail, I., Raya, I., & Kandeel, M. (2024). The synergy of artificial intelligence and personalized medicine for the enhanced diagnosis, treatment, and prevention of disease. *Drug Metabolism and Personalized Therapy*, *39*(2), 47-58.
110. Zargaran, A.; Sousi, S.; Glynou, S.P.; Mortada, H.; Zargaran, D.; Mosahebi, A. A systematic review of generative adversarial networks (GANs) in plastic surgery. J. Plast. Reconstr. Aesthetic Surg. 2024, 95, 377–385.
111. Živanović, M. N., & Filipović, N. (2024). System Biology Modeling for Drug Optimization. In *In Silico Clinical Trials for Cardiovascular Disease: A Finite Element and Machine Learning Approach* (pp. 105-137). Cham: Springer Nature Switzerland.